Impairment of aldehyde dehydrogenase-2 by 4-hydroxy-2-nonenal adduct formation and cardiomyocyte hypertrophy in mice fed a high-fat diet and injected with low-dose streptozotocin

Experimental Biology and Medicine

Volumn 239, Issue 5, 2014, Pages 610-618

  Mali, Vishal R ^a   Ning, Ruizhuo ^b   Chen, Jieli ^b   Yang, Xiao Ping ^a   Xu, Jiang ^a   Palaniyandi, Suresh S ^a,c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4 hydroxy 2 nonenal; Aldehyde dehydrogenase 2; cardiomyocyte hypertrophy; diabetic cardiac complications; metabolic syndrome; type 2 diabetes mellitus

Indexed keywords

4 HYDROXYNONENAL; ALDEHYDE DEHYDROGENASE ISOENZYME 2; INSULIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DNA ADDUCT; ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; HYPERGLYCEMIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INFANT; INSULIN RESISTANCE; LIPID DIET; MALE; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; WESTERN BLOTTING;

4-HYDROXY-2-NONENAL; ALDEHYDE DEHYDROGENASE 2; CARDIOMYOCYTE HYPERTROPHY; DIABETIC CARDIAC COMPLICATIONS; METABOLIC SYNDROME; TYPE-2 DIABETES MELLITUS;

ALDEHYDE DEHYDROGENASE; ALDEHYDES; ANIMALS; CARDIOMEGALY; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; STREPTOZOCIN;

EID: 84899667648     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213520109     Document Type: Article

References (57)

1. Singh R,Barden A,Mori T,Beilin L.Advanced glycation end-products: a review.Diabetologia. 2001;44:129-46.
2. Yamagishi S,Nakamura K,Matsui T.Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.Pharmacol Res. 2009;60:174-8.
3. Sourris KC,Harcourt BE,Forbes JM.A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?.Am J Nephrol. 2009;30:323-35.
4. Cohn JA,Tsai L,Friguet B,Szweda LI.Chemical characterization of a protein-4-hydroxy-2-nonenal cross-link: immunochemical detection in mitochondria exposed to oxidative stress.Arch Biochem Biophys. 1996;328:158-64.
5. Eaton P,Li JM,Hearse DJ,Shattock MJ.Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart.Am J Physiol. 1999;276:H935-43.
6. Esterbauer H,Schaur RJ,Zollner H.Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes.Free Radic Biol Med. 1991;11:81-128.
7. Forbes SP,Druhan LJ,Guzman JE,Parinandi N,Zhang L,Green-Church KB,Cardounel AJ.Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation.Biochemistry. 2008;47:1819-26.
8. Isom AL,Barnes S,Wilson L,Kirk M,Coward L,Darley-Usmar V.Modification of Cytochrome c by 4-hydroxy-2-nonenal: evidence for histidine, lysine, and arginine-aldehyde adducts.J Am Soc Mass Spectrom. 2004;15:1136-47.
9. Roede JR,Jones DP.Reactive species and mitochondrial dysfunction: mechanistic significance of 4-hydroxynonenal.Environ Mol Mutagen. 2010;51:380-90.
10. Calabrese V,Mancuso C,Sapienza M,Puleo E,Calafato S,Cornelius C,Finocchiaro M,Mangiameli A,Di Mauro M,Stella AM,Castellino P.Oxidative stress and cellular stress response in diabetic nephropathy.Cell Stress Chaperones. 2007;12:299-306.
11. Uchida K.Role of reactive aldehyde in cardiovascular diseases.Free Radic Biol Med. 2000;28:1685-96.
12. Cantero AV,Portero-Otin M,Ayala V,Auge N,Sanson M,Elbaz M,Thiers JC,Pamplona R,Salvayre R,Negre-Salvayre A.Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis.FASEB J. 2007;21:3096-106.
13. Vasiliou V,Pappa A,Petersen DR.Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism.Chem Biol Interact. 2000;129:1-19.
14. Chen CH,Budas GR,Churchill EN,Disatnik MH,Hurley TD,Mochly-Rosen D.Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.Science. 2008;321:1493-5.
15. Ma H,Guo R,Yu L,Zhang Y,Ren J.Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde.Eur Heart J. 2011;32:1025-38.
16. Palaniyandi SS,Marie-Helene D,Sun L,Vishnumangalam JJ,Xia X,Pavlovic A,Bhalla V,Ashley E,Mochly-Rosen D.Aldehyde dehydrogenase activator attenuates diabetic cardiomyopathy; a role in improving the quality of resident cardiac stem cells?.FASEB J. 2010;24:572.3-572.3.
17. Zhang Y,Ren J.Autophagy in ALDH2-elicited cardioprotection against ischemic heart disease: slayer or savior?.Autophagy. 2010;6:1212-3.
18. Zhang Y,Ren J.ALDH2 in alcoholic heart diseases: molecular mechanism and clinical implications.Pharmacol Ther. 2011;132:86-95.
19. Chang YC,Chiu YF,Lee IT,Ho LT,Hung YJ,Hsiung CA,Quertermous T,Donlon T,Lee WJ,Lee PC,Chen CH,Mochly-Rosen D,Chuang LM.Common ALDH2 genetic variants predict development of hypertension in the SAPPHIRe prospective cohort: gene-environmental interaction with alcohol consumption.BMC Cardiovasc Disord. 2012;12:58-58.
20. Murata C,Watanabe T,Furuya H,Sugioka Y,Mikurube H,Yokoyama A,Atsumi Y,Matsuoka K,Okazaki I.Aldehyde dehydrogenase 2 and beta3-adrenergic receptor gene polymorphisms: their association with elevated liver enzymes and metabolic syndrome.Metabolism. 2003;52:1096-101.
21. Murata C,Taniyama M,Kuriyama S,Muramatsu T,Atsumi Y,Matsuoka K,Suzuki Y.Meta-analysis of three diabetes population studies: association of inactive ALDH2 genotype with maternal inheritance of diabetes.Diabetes Res Clin Pract. 2004;66:S145-7.
22. Suzuki Y,Taniyama M,Muramatsu T,Higuchi S,Ohta S,Atsumi Y,Matsuoka K.ALDH2/ADH2 polymorphism associated with vasculopathy and neuropathy in type 2 diabetes.Alcohol Clin Exp Res. 2004;28:111S-6S.
23. Zhang Y,Babcock SA,Hu N,Maris JR,Wang H,Ren J.Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3beta and mitochondrial function.BMC Med. 2012;10:40-40.
24. Wang J,Wang H,Hao P,Xue L,Wei S,Zhang Y,Chen Y.Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats.Mol Med. 2011;17:172-9.
25. Hamblin M,Friedman DB,Hill S,Caprioli RM,Smith HM,Hill MF.Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy.J Mol Cell Cardiol. 2007;42:884-95.
26. Lashin OM,Szweda PA,Szweda LI,Romani AM.Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart.Free Radic Biol Med. 2006;40:886-96.
27. Panchal SK,Brown L.Rodent models for metabolic syndrome research.J Biomed Biotechnol. 2011;2011:351982-351982.
28. Surwit RS,Kuhn CM,Cochrane C,McCubbin JA,Feinglos MN.Diet-induced type II diabetes in C57BL/6J mice.Diabetes. 1988;37:1163-7.
29. Winzell MS,Ahren B.The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes.Diabetes. 2004;53:S215-9.
30. Reed MJ,Meszaros K,Entes LJ,Claypool MD,Pinkett JG,Gadbois TM,Reaven GM.A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat.Metabolism. 2000;49:1390-4.
31. Srinivasan K,Viswanad B,Asrat L,Kaul CL,Ramarao P.Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening.Pharmacol Res. 2005;52:313-20.
32. Zhang M,Lv XY,Li J,Xu ZG,Chen L.The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model.Exp Diabetes Res. 2008;2008:704045-704045.
33. Arulmozhi DK,Kurian R,Bodhankar SL,Veeranjaneyulu A.Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.J Pharm Pharmacol. 2008;60:1167-73.
34. Hsueh W,Abel ED,Breslow JL,Maeda N,Davis RC,Fisher EA,Dansky H,McClain DA,McIndoe R,Wassef MK,Rabadán-Diehl C,Goldberg IJ.Recipes for creating animal models of diabetic cardiovascular disease.Circ Res. 2007;100:1415-27.
35. Selvakumar D,Drescher MJ,Dowdall JR,Khan KM,Hatfield JS,Ramakrishnan NA,Drescher DG.CNGA3 is expressed in inner ear hair cells and binds to an intracellular C-terminus domain of EMILIN1.Biochem J. 2012;443:463-76.
36. Palaniyandi SS,Nagai Y,Watanabe K,Ma M,Veeraveedu PT,Prakash P,Kamal FA,Abe Y,Yamaguchi K,Tachikawa H,Kodama M,Aizawa Y.Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats.Exp Biol Med (Maywood). 2007;232:1213-221.
37. Yang XP,Liu YH,Rhaleb NE,Kurihara N,Kim HE,Carretero OA.Echocardiographic assessment of cardiac function in conscious and anesthetized mice.Am J Physiol. 1999;277 (5 Pt 2): H1967-74.
38. Jo SA,Kim EK,Park MH,Han C,Park HY,Jang Y,Song BJ,Jo I.A Glu487Lys polymorphism in the gene for mitochondrial aldehyde dehydrogenase 2 is associated with myocardial infarction in elderly Korean men.Clin Chim Acta. 2007;382:43-7.
39. Takagi S,Iwai N,Yamauchi R,Kojima S,Yasuno S,Baba T,Terashima M,Tsutsumi Y,Suzuki S,Morii I,Hanai S,Ono K,Baba S,Tomoike H,Kawamura A,Miyazaki S,Nonogi H,Goto Y.Aldehyde dehydrogenase 2 gene is a risk factor for myocardial infarction in Japanese men.Hypertens Res. 2002;25:677-81.
40. Furfaro AL,Menini S,Patriarca S,Pesce C,Odetti P,Cottalasso D,Marinari UM,Pronzato MA,Traverso N.HNE-dependent molecular damage in diabetic nephropathy and its possible prevention by N-acetyl-cysteine and oxerutin.Biofactors. 2005;24:291-8.
41. Amamoto K,Okamura T,Tamaki S,Kita Y,Tsujita Y,Kadowaki T,Nakamura Y,Ueshima H.Epidemiologic study of the association of low-Km mitochondrial acetaldehyde dehydrogenase genotypes with blood pressure level and the prevalence of hypertension in a general population.Hypertens Res. 2002;25:857-64.
42. Lagranha CJ,Deschamps A,Aponte A,Steenbergen C,Murphy E.Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females.Circ Res. 2010;106:1681-91.
43. Ma H,Li J,Gao F,Ren J.Aldehyde dehydrogenase 2 ameliorates acute cardiac toxicity of ethanol: role of protein phosphatase and forkhead transcription factor.J Am Coll Cardiol. 2009;54:2187-96.
44. Hintz KK,Relling DP,Saari JT,Borgerding AJ,Duan J,Ren BH,Kato K,Epstein PN,Ren J.Cardiac overexpression of alcohol dehydrogenase exacerbates cardiac contractile dysfunction, lipid peroxidation, and protein damage after chronic ethanol ingestion.Alcohol Clin Exp Res. 2003;27:1090-8.
45. Li SY,Gilbert SA,Li Q,Ren J.Aldehyde dehydrogenase-2 (ALDH2) ameliorates chronic alcohol ingestion-induced myocardial insulin resistance and endoplasmic reticulum stress.J Mol Cell Cardiol. 2009;47:247-55.
46. Horie K,Miyata T,Maeda K,Miyata S,Sugiyama S,Sakai H,van Ypersole de Strihou C,Monnier VM,Witztum JL,Kurokawa K.Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy.J Clin Invest. 1997;100:2995-3004.
47. Xiao J,Lv Y,Lin S,Jin L,Zhang Y,Wang X,Ma J,Hu K,Feng W,Cai L,Li X,Tan Y.Cardiac protection by basic fibroblast growth factor from ischemia/reperfusion-induced injury in diabetic rats.Biol Pharm Bull. 2010;33:444-9.
48. Ye G,Metreveli NS,Donthi RV,Xia S,Xu M,Carlson EC,Epstein PN.Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes.Diabetes. 2004;53:1336-43.
49. Lucas DT,Szweda LI.Cardiac reperfusion injury: aging, lipid peroxidation, and mitochondrial dysfunction.Proc Natl Acad Sci U S A. 1998;95:510-4.
50. Bardag-Gorce F,Li J,French BA,French SW.The effect of ethanol-induced CYP2E1 on proteasome activity: the role of 4-hydroxynonenal.Exp Mol Pathol. 2005;78:109-15.
51. Ferrington DA,Kapphahn RJ.Catalytic site-specific inhibition of the 20S proteasome by 4-hydroxynonenal.FEBS Lett. 2004;578:217-23.
52. Nakamura K,Miura D,Kusano KF,Fujimoto Y,Sumita-Yoshikawa W,Fuke S,Nishii N,Nagase S,Hata Y,Morita H,Matsubara H,Ohe T,Ito H.4-Hydroxy-2-nonenal induces calcium overload via the generation of reactive oxygen species in isolated rat cardiac myocytes.J Card Fail. 2009;15:709-16.
53. Traverso N,Menini S,Odetti P,Pronzato MA,Cottalasso D,Marinari UM.Diabetes impairs the enzymatic disposal of 4-hydroxynonenal in rat liver.Free Radic Biol Med. 2002;32:350-9.
54. Feng B,Chen S,Chiu J,George B,Chakrabarti S.Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level.Am J Physiol Endocrinol Metabol. 2008;294:E1119-26.
55. Camp TM,Tyagi SC,Senior RM,Hayden MR.Gelatinase B(MMP-9) an apoptotic factor in diabetic transgenic mice.Diabetologia. 2003;46:1438-45.
56. Salem KA,Kosanovic M,Qureshi A,Ljubisavljevic M,Howarth FC.The direct effects of streptozotocin and alloxan on contractile function in rat heart.Pharmacol Res. 2009;59:235-41.
57. Wold LE,Ren J.Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism.Biochem Biophys Res Commun. 2004;318:1066-71.